Showing results (201-210 of 277) with videos related to

Sort By:
Pageof 28
Advances in Therapy|May 3, 2025
Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up AnalysisLijuan Deng, Yuqin Song, Keshu Zhou, et al.
BMC Cancer|September 23, 2018
PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivityWen Zheng, Yuhuan Gao, Xiaoyan Ke, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|March 31, 2022
A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphomaZhitao Ying, Ting He, Shanzhao Jin, et al.
Blood Advances|October 12, 2021
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphomaHaiyan Yang, Bing Xiang, Yuqin Song, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2026
Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase InhibitorToby A Eyre, Yuqin Song, Olivier Hermine, et al.
Cancer Medicine|April 14, 2020
Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decadesWeiping Liu, Xinqiang Ji, Yuqin Song, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|April 21, 2016
[Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma]Weiping Liu, Xiaopei Wang, Chen Zhang, et al.
International Journal of Cancer|October 21, 2021
Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow-up of the multicenter, single-arm, Phase 2 studyJianqiu Wu, Yuqin Song, Xinchuan Chen, et al.
British Journal of Pharmacology|February 23, 2026
Development of a novel tyrosine kinase 2 inhibitor ARTS-011 and its first-in-human single and multiple ascending dose Phase I study to evaluate the tolerability, safety, pharmacokinetic profile and food effectsZhili Jin, Jingxuan Wu, Jiaqi Liang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2019
A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin LymphomaYuqin Song, Jianqiu Wu, Xinchuan Chen, et al.
Pageof 28